SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.96-1.3%10:24 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: greedsgd_2000 who wrote (1922)11/2/2000 4:48:25 PM
From: Torben Noerup Nielsen   of 52153
 
According to the Nature Biotechnology Supplement (October 2000), rheumatoid arthritis affects about 1% of the world's population and is twice as prevalent in women as in men.

This treatment is interesting since it is treating the cause rather than ameliorating the symptoms.

But it is worrisome due to cost. If we choose to freeze the standard of health care as of some arbitrary date, say 12/31/1999, then I'm quite sure that we could actually bring health care costs down over time. But since we are forging ahead with new and improved treatments, it isn't realistic to expect health care costs to stay unchanged. The funds need to come from somewhere. We already have a few different standards of care around. Will we get more?

You would probably get the greatest kick from something like an HIV vaccine although I would regard a full cure for arthritis as being far more significant.

Thanks, Torben
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News